As such, novel ways to target myeloid cell infiltration, such as the new CCR2 inhibitor used here, or through manipulation of key signaling pathways such as IL-33 signaling, appear to be viable strategies for improving outcomes in PDA. Here, IL33 is linked to Patent ductus arteriosus.